CAMBRIDGE, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ: EDIT), a leading
genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board of Directors, effective immediately.
Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He is the Gerald and Darlene Jordan Professor of Medicine and is Professor of Stem Cell and Regenerative Biology at Harvard University. He co-founded and co-directs…
